Clinical Trials Logo

Rheumatic Diseases clinical trials

View clinical trials related to Rheumatic Diseases.

Filter by:

NCT ID: NCT03762824 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease

IPS-BOOSTER
Start date: June 14, 2016
Phase: Phase 4
Study type: Interventional

The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on antibody response elicited by pneumococcal vaccination using 13-valent conjugate vaccine in combined schedules with 23-valent polysaccharide vaccine. In addition, the aim is to study the clinical aspects of vaccination regarding: tolerability in immunosuppressed patients with IRD, impact on existing rheumatic disease, possible association with onset of new autoimmune diseases, long-term immunity following pneumococcal vaccination and efficacy in preventing invasive pneumococcal disease. Results from this study are expected to bridge the existing knowledge gap and contribute to body of evidence needed for recommendations and implementation of vaccination program in IRD patients.

NCT ID: NCT03753893 Active, not recruiting - Macular Edema Clinical Trials

Ocular Manifestations in Rheumatic Diseases

Start date: May 1, 2013
Phase:
Study type: Observational

This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

NCT ID: NCT03751644 Recruiting - Rheumatic Diseases Clinical Trials

Peripherical Neuromuscular Electrical Stimulation in Systemic Autoimmune Myopathies

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

Systemic autoimmune myopathies are a heterogeneous group of rheumatic diseases with progressive skeletal muscle weakness. The relevance of the peripherical neuromuscular electrical stimulation has never applied in the patients with systemic autoimmune myopathies. Therefore, the main objective of the present prospective, randomized, investigator-blind, placebo-controlled study is to evaluate the safety and efficacy of the application of an acute peripherical neuromuscular electrical stimulation session in patients with systemic autoimmune myopathies.

NCT ID: NCT03736278 Not yet recruiting - Tuberculosis Clinical Trials

Characteristics of Tuberculosis Infection in Rheumatic Disease

Start date: November 5, 2018
Phase:
Study type: Observational

A retrospective study evaluating the characteristics of tuberculosis infection in patients of rheumatic disease.

NCT ID: NCT03728231 Not yet recruiting - Rheumatic Diseases Clinical Trials

Disease Activity in RA and SLE Patients and Its Relation to Muscle Performance,Fatigue and Blood Parameters

Start date: November 15, 2018
Phase:
Study type: Observational

Assessment of disease activity in Rheumatoid Arthritis and Systemic lupus patients related to muscle performance, fatigue and blood parameters

NCT ID: NCT03669367 Not yet recruiting - Clinical trials for Palindromic Rheumatism, Wrist

EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)

PALABA
Start date: December 1, 2018
Phase: Phase 4
Study type: Interventional

The main objective of this trial is to test the hypothesis that abatacept can reduce the progression of rheumatoid arthritis in ACPA+ or RF+ patients with palindromic rheumatism compared with patients treated with hydroxychloroquine.

NCT ID: NCT03589300 Recruiting - Clinical trials for Rheumatoid Arthritis

Persona TM Tibia Clinical Outcomes Study

Start date: April 30, 2018
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate clinical performance for the commercially available Persona TM Tibia used in primary cementless tibia total knee arthroplasty.

NCT ID: NCT03558971 Completed - Rheumatic Diseases Clinical Trials

Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17

Start date: January 1, 2000
Phase: Phase 4
Study type: Interventional

Participants diagnosed as having fibromyalgia, osteoarthritis, and rheumatoid arthritis are to be brought to a minimum symptom state using a 3-week period during which they are to ingest modest doses of cortisol tablets with weekly lowered tapered doses. Thereafter, the participants are to be taught to self-administer cortisol tablets on the as-needed basis to maintain the minimum symptom state. For this, they are to ingest a smaller-dosage, 5-day tapered regimen of cortisol tablets to quench each reoccurring exacerbation of the disease at its earliest stage. Participants are limited to using less than the safe use limit of cortisol per month and are required to include a minimum of 10 days per month during which no cortisol was ingested.

NCT ID: NCT03549052 Not yet recruiting - Clinical trials for Right Ventricular Dysfunction

Right Ventricular Echo Assessment in Mitral Valve Replacement

Start date: June 1, 2018
Phase:
Study type: Observational

Rheumatic heart disease remains a major health problem in developing countries. It is the most important sequel of rheumatic fever and occurs in about 30% of patients with rheumatic fever.Rheumatic heart disease presents with different degrees of pancarditis and associated valve failure. Involvement of the mitral leaflets can cause mitral regurgitation (MR) or stenosis and eventually can lead to heart failure. Mitral repair or replacement is therefore recommended before left ventricular (LV) dysfunction develops. Study Objectives/Specific Aims Overall Goal: To determine the benefit the patient with pulmonary hypertension will get from mitral valve replacement as regard function improvement and remodeling of the right ventricle. - Objective1: Identify risk factors that are predictive of outcomes.(Type and severity of Mitral valve pathology , severity of pulmonary hypertension, tricuspid regurge, preoperative RV dysfunction) - Objective2: Determine the value of management strategies (Mitral valve replacement in pulmonary hypertension i.e. : decrease RV pressure overload and enhance RV remodeling) - Objective3: Assessment of the outcomes clinically & Echocardiographically : postoperative results during hospital stay and follow up (short term up to 3 months).

NCT ID: NCT03538470 Not yet recruiting - Clinical trials for Osteoarthritis, Knee

Assessment of the Effect of Spa Treatment on Rheumatological Conditions

CONTREXEVILLE
Start date: June 2018
Phase: N/A
Study type: Interventional

1. Primary outcome measure: measuring the effect of spa treatment in patients suffering from lower limb osteoarthritis or any other lower limb rheumatological condition. Percentage of patients with minimum 19,9 mm decrease in pain Visual Analogue Scale (VAS) or WOMAC score (Western Ontario and McMaster Universities Arthritis Index) increase of at least 9 points (minimal clinically important difference), 6 months after enrollment. Secondary outcome measures: 2. Measuring the effect of spa treatment in patients with concomitant chronic lower back pain. Percentage of patients presenting clinical benefits according to the EIFEL score, with a decrease of at least 5 points, 6 months after enrollment. 3. Quantitative evaluation of pain. Mean pain VAS comparison between enrollment and 6 months after spa treatment. 4. Quantitative evaluation of WOMAC score. Mean WOMAC score comparison between enrollment and 6 months after spa treatment. 5. Quantitative evaluation of EIFEL score. Mean EIFEL score comparison between enrollment and 6 months after spa treatment. 6. Impact of spa treatment on the patient's metabolism. Height and weight (BMI calculation), blood pressure and heart rate measured at enrollment and throughout the follow-up. 7. 8. Quality of life. 36-Item Short Form (SF 36) and EuroQol 5 Dimensions (EQ5D) questionnaires at enrollment, 3 months and 6 months. 9. Doctor and patient opinion. Semi-quantitative scale collected at enrollment, 3 months and 6 months. 10. Medicine consumption Daily medicine consumption evaluated upon the 72 hours preceding the medical visit at enrollment, 3 months and 6 months. 11. Auto-evaluation of pain VAS pain evaluation by the patient every 6 weeks for a more precise time frame of the treatment's effect.